Sennoside A is a novel inhibitor targeting caspase-1. Issue 19 (13th September 2022)

• Record Type: Journal Article
• Authors: Wu, Jiasi; Lan, Yuejia; Shi, Xiaoke; Huang, Wenge; Li, Sheng; Zhang, Jizhou; Wang, Huan; Wang, Fei; Meng, Xianli
• Is Part Of: Food & function. Volume 13:Issue 19(2022)
• Page Start: 9782
• Page End: 9795
• Publication Date: 2022-09-13
• Subjects: Food -- Analysis -- Periodicals; Food -- Composition -- Periodicals; Nutrition -- Periodicals; 664.07
• DOI: 10.1039/d2fo01730j
• Languages: English
• ISSNs: 2042-6496

Abstract

Abstract : Sen A decreases caspase-1 activity and P2X7 function, which further leads to NLRP3 and AIM2 inflammasome disassembly and the reduced secretion of IL-1β and IL-18 via pyroptosis restraining and NF-κB-involved NLRP3 priming. Abstract : The assembly of inflammasomes drives caspase-1 activation, which further promotes proinflammatory cytokine secretion and downstream pyroptosis. The discovery of novel caspase-1 inhibitors is pivotal to developing new therapeutic means for inflammasome-involved diseases. In our present study, sennoside A (Sen A), a popular ingredient in multiple weight-loss medicines and dietary supplements, is found to potently inhibit the enzymatic activity of caspase-1 in vitro . Sen A considerably decreased IL-1β production in macrophages stimulated by LPS plus ATP, nigericin or MSU as well as poly(dA:dT) transfection, and remedied ROS-involved pyroptosis via caspase-1 inhibition. Mechanistically, Sen A not only suppressed the assembly of both NLRP3 and AIM2 inflammasome but also affected the priming process of NLRP3 inflammasome by blocking NF-κB signaling. Sen A significantly ameliorated the pathophysiological effect in LPS-, MSU- and carrageenan-challenged rodent models by suppressing inflammasome activation. Furthermore, P2X7 was indispensable for Sen A inhibiting NLRP3 inflammasome since it failed to further decrease IL-1β and IL-18 production in LPS plus ATP-stimulated BMDMs that were transfected with P2X7 siRNA. Sen A also restrained the large pore-forming functionalities of the P2X7R as verified by the YO-PRO-1 uptake assay. Taken together, Sen A inactivates caspase-1 to inhibit NLRP3 and AIM2 inflammasome-involved inflammation in a P2X7-dependent manner, making it an attractive candidate as a caspase-1 small-molecular inhibitor.